Fate Therapeutics Inc.
FATE | NASDAQ
$2.52
-$0.01 (-0.40%)
Sep 22, 2026, 9:35 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 6.65M | 13.63M | 63.53M | 96.3M | 55.85M | 31.43M |
Cost of Revenue | 12.9M | 118.53M | 157.19M | 13.76M | 5.85M | 125.62M |
Gross Profit | -6.26M | -104.9M | -93.65M | 82.54M | 50M | -94.19M |
Operating Income | -147.7M | -210.28M | -190.51M | -308.39M | -216.99M | -128.09M |
Interest Income | 11.05M | 17.29M | 17.19M | 5.84M | 1.31M | 2.4M |
Pretax Income | -136.32M | -186.26M | -160.93M | -281.72M | -212.15M | -173.39M |
Net Income | -136.32M | -186.26M | -160.93M | -281.72M | -212.15M | -173.39M |
Selling & General & Admin | 46.52M | 90.64M | 96.86M | 84.23M | 57.32M | 33.9M |
Research & Development | 107.83M | 135M | 172.6M | 320.45M | 215.52M | 125.62M |
Other Expenses | -12.9M | -120.26M | -172.6M | -13.76M | -5.85M | -125.62M |
Operating Expenses | 141.45M | 105.38M | 96.86M | 390.93M | 266.99M | 33.9M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | 16.47M | 15.41M | n/a | n/a | n/a |
Cost & Expenses | 154.35M | 223.91M | 254.04M | 404.69M | 272.84M | 159.52M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 118.79M | 113.69M | 98.41M | 96.83M | 94.75M | 82.39M |
Shares Outstanding (Diluted) | 118.79M | 113.69M | 98.41M | 96.83M | 94.75M | 82.39M |
EPS (Basic) | -1.15 | -1.64 | -1.64 | -2.91 | -2.24 | -2.10 |
EPS (Diluted) | -1.15 | -1.64 | -1.64 | -2.91 | -2.24 | -2.10 |
EBITDA | -127.02M | -176.58M | -142.65M | -267.96M | -206.3M | -125M |
EBIT | -136.32M | -195.54M | -160.93M | -281.72M | -212.15M | -128.09M |
Depreciation & Amortization | 9.3M | 18.96M | 18.28M | 13.76M | 5.85M | 3.09M |
Add to Watchlist
Select watchlists to add or remove FATE